Q-omics provides the consensus-scored ROS1 profile across patient tissues and cancer cell-line models. ROS1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ROS1 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, ROS1 RNA expression shows 15,961 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, COAD, and LSCC as cancer lineages where ROS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ROS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ROS1 survival associations across molecular data types. ROS1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (12) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ROS1 RNA expression–survival associations across cancer types. High ROS1 expression shows unfavorable associations in KIRC, KIRP, LUSC, KICH, MESO and STAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ROS1 RNA expression.
This table summarizes ROS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ROS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ROS1 shows lower tumor expression in COAD, KIRC, LUAD, KICH and LUSC and higher tumor expression in HNSC. The COAD box plot shows higher ROS1 RNA expression in normal versus tumor tissue (log2 FC = −0.428, t-test p < 0.001).
This table shows molecular features associated with ROS1 in patient tissues and cancer cell lines. In patient samples, ROS1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ROS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
